World's Vaccine Industry Leaders to Gather at VacChina 2010

SHANGHAI, April 16 /PRNewswire-Asia/ -- Hosted by Global Leaders Institute, "VacChina 2010", a Vaccine Development Summit to be held from September 15-16, 2010, will bring together the world's major vaccine players and their respective senior level representatives to Shanghai, the heart of China's biopharmaceutical innovation.

China's vaccine industry has been under a spotlight following the recent events of Novartis-Zhejiang Tianyuan deal and GSK-Yunan Walvax JV.

Dr. Daniel Vasella, Chairman and CEO of Novartis commented, "Novartis has a long-standing commitment to improving healthcare in China. Our future activities with Tianyuan are an important step in our strategy to enhance the prevention of diseases in China with high-quality products."

"The joint venture would help bring more of GSK's technologies to China," added GlaxoSmithKline CEO Andrew Witty. GSK also signed a deal with Yunnan Walvax Biotech in October to co-launch a company that focuses on pediatric vaccines, with an initial investment of 451 million yuan from the two companies.

Over 200 senior executives from international vaccine suppliers including GlaxoSmithKline, Sanofi Pasteur, Novartis, Merck, Pfizer, Crucell, MedImmune, Intercell, as well as domestic leaders including Sinopharm, Sinovac, Hualan Bioengineering, Zhejiang Tianyuan Biopharmaceuticals, Tiantan Bio, Yunan Walvax and Simcere will present at the event.

Following the recent vaccine safety incidents in Shanxi and Jiangsu, safety issues have been brought to the top of agenda for first time. A roundtable housing a panel of China's vaccine industry leaders and experts from the Chinese Center for Disease Control and Prevention will join the discussion on strategies employed in ensuring efficacious and safe vaccines.

"VacChina 2010" Vaccine Development Summit brings together thought leaders from the world's leading vaccine manufacturers, biotechs, service providers, governmental agencies, research and academic institutes.

    For further information, please contact:

     Daniel Chen
     Global Leaders Institute
     Tel:   +86-21-3251-6046
     Email: [email protected]

SOURCE Global Leaders Institute

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.